ATS 2019 Call for Abstracts and Case Reports Now Open

The American Thoracic Society is now accepting scientific abstracts and case reports for consideration for the ATS 2019 International Conference, May 17–22, in Dallas, Texas!
The ATS International Conference is the longest running, large-scale conference in the world and hosts more than 14,000 attendees working in pulmonary, critical care, and sleep medicine. The ATS is seeking:

• Scientific Abstracts, which can report on basic, translational, and clinical science research; epidemiologic, social, biobehavioral, and psychosocial investigations; or educational and quality improvement projects.
• Case Reports, which must describe a single, unique case.

Submit by Wednesday, Oct. 31, 5 p.m. ET.
See complete submission guidelines.

2018 Latin American Critical Care Conference

Join the ATS, the Sociedade Brasileira de Pneumologia e Tisiologia, and Asociacón Latinoamericana de Tórax (ALAT) for the  2018 Latin American Critical Care Conference, “Treatment of the Acutely Decompensating Patient: Best Practices for Mechanical Ventilation,” this September in São Paulo, Brazil.

When: September 6-8, 2018

Where: São Paulo, Brazil

ATS Foundation Elects Five New Board Members

The ATS Foundation is pleased to announce the addition of five new members to the Board of Trustees: Chris Blango, Jeffrey Goldstein, Stuart Loesch, Greg Lund, and Julie Vu. The Board provides leadership for carrying out the Foundation’s mission to fund research, education, and training to prevent, treat, and cure respiratory diseases worldwide.

“I am pleased to welcome Chris, Jeffrey, Stuart, Greg, and Julie as new Board members,” said Dean Schraufnagel, MD, chair of the ATS Foundation. “These individuals bring a wealth of experience and expertise in their fields and will be tremendous assets to our Foundation and our commitment to building a future where patients breathe better”.

The ATS supports the ATS Foundation’s administrative expenses, assuring that every dollar contributed goes directly to support programs.

Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, announced that the Data Monitoring Committee (DMC) has recommended that the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH) be stopped for futility. The recommendation came after the DMC completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH).  INOpulse® was well-tolerated and there were no safety concerns that led the DMC to recommend concluding the trial.

However, based on the results of the Phase 2 studies in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), Bellerophon Therapeutics, Inc. is continuing other INOpulse® programs. The ongoing Phase 2b trial in PH-ILD is progressing well, with results expected around the end of 2018.

Registration Open for NIH Workshop on Single IRB Resource and Infrastructure Development

NIH will be holding a public workshop on successful strategies and lessons learned for modifying and enhancing institutional IRB infrastructure for single IRB review of multi-site studies.
The “Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research,” establishes the expectation that the domestic sites of all NIH-funded multisite studies involving non-exempt human subjects research will use a single Institutional Review Board.

NIH previously funded seven administrative supplements that provided one year of support to develop widely applicable approaches for modifying and enhancing institutional IRB infrastructure and related resources to allow for efficient and effective single IRB review of multi-site studies. This workshop will bring together those awardees to share the innovative strategies they have developed.

When: September 12, 2018
Where: Online and at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center Rockville, 1750 Rockville Pike, MD.